Those at highest risk for severe COVID-19 often least likely to get monoclonal antibodies, study finds

People over age 65 at the highest risk for severe COVID-19 have often been the least likely to receive monoclonal antibodies (mAbs) -- a highly effective treatment for the disease -- both across and within U.S. states, according to new research.